BioNTech to target supply of up to 2 billion doses of COVID-19 vaccine in 2021

/ / News

Germany’s BioNTech SE said Monday it is aiming to supply up to 2 billion doses of its COVID-19 vaccine in 2021, after receiving emergency use authorization in both the U.S. and EU. In a regulatory filing, the company said it has committed to supplying more than 1 billion doses of the vaccine, which it co-developed with Pfizer Inc. . The partners are making the vaccine at six manufacturing sites and are aiming to expand the label to include pediatric indications, pregnant women and other sub-populations. BioNTech shares were up 1.4% premarket and have gained 153% in the last 12 months, while the SPDR S&P Biotech ETF has gained 58% and the S&P 500 has gained 17%.
Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.